FDA DELAYS its decision on Moderna vaccine use for children aged 12 to 17 to evaluate myocarditis risk, says firm

The FDA announced it will delay its decision on whether children ages 12 to 17 should receive the Moderna COVID-19 vaccine to determine if the shot increases the risk of a rare side effect that impacts kids’ hearts, the agency said Sunday. The announcement comes just three days after the FDA authorized Pfizer-BioNTech’s COVID-19 vaccine for children between ages … Continue reading FDA DELAYS its decision on Moderna vaccine use for children aged 12 to 17 to evaluate myocarditis risk, says firm